Trials / Unknown
UnknownNCT04928690
Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping
Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping (EARS)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 140 (estimated)
- Sponsor
- Novoic Limited · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- —
Summary
The S22 study investigates, in a cross-sectional study, the ability of algorithms that analyse acoustic and linguistic patterns of spoken language to predict the presence of amyloid positivity in early stage Alzheimer's disease, specifically in Mild Cognitive Impairment (MCI) and cognitively normal (CN) cohorts; and whether similar algorithms can predict cognitive functioning, in classifying MCI vs CN.
Conditions
Timeline
- Start date
- 2021-06-20
- Primary completion
- 2021-08-15
- Completion
- 2022-08-30
- First posted
- 2021-06-16
- Last updated
- 2021-06-16
Source: ClinicalTrials.gov record NCT04928690. Inclusion in this directory is not an endorsement.